Due to a lack of known efficacious agents early in the 2019 coronavirus disease (COVID-19) pandemic and retrospective data suggesting the benefit of CP in previous viral outbreaks, the Food and Drug Administration (FDA) approved an expanded access program (EAP) for COVID-19 CP therapy for critically ill COVID patients in March 2020 [3]. Here, CP is linked to glycogen storage disease VI.